Guangzhou Boyuan Outdoor Products Co., Ltd. is a trading company headquartered in Guangzhou, one of southern China's most prominent commercial and logistics hubs. Leveraging the city's well-established supply chain infrastructure and international trade channels, the company has evolved from its original focus on outdoor consumer goods into a specialized supplier of high-purity biochemical reagents and peptide derivatives. While the company retains "Outdoor Products" in its registered name, its current core business centers on providing stable, non-hazardous, and laboratory-grade peptide derivatives to qualified research institutions, universities, and commercial laboratories worldwide.
Boyuan operates under a clear and responsible business philosophy: professionalism, consistency, and traceability. All products offered by the company are positioned strictly as general chemical reagents and laboratory research materials. They are not classified as pharmaceuticals, medical devices, hazardous chemicals, or products intended for human therapeutic, diagnostic, or preventive applications. The company strictly adheres to national and international regulations governing the trade and logistics of non-hazardous chemical products, ensuring that every step—from procurement and quality inspection to warehousing and domestic or international shipping—remains compliant, safe, and fully traceable.
Retatrutide is a synthetic peptide consisting of 39 amino acids, and its chemical structure incorporates several key modifications that differentiate it from native GIP, GLP-1, and glucagon. One of the most important modifications is the attachment of a fatty diacid moiety to the side chain of a lysine residue, which promotes strong binding to serum albumin and significantly extends the plasma half-life of Retatrutide to approximately six days. This extended half-life supports once-weekly dosing in research settings and makes Retatrutide an excellent tool for long-term in vitro and in vivo studies requiring sustained receptor activation. Additionally, the amino acid sequence of Retatrutide incorporates specific substitutions that enhance its stability against enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). Unlike native GIP and GLP-1, which are rapidly degraded by DPP-4, Retatrutide maintains high resistance to enzymatic cleavage, resulting in prolonged biological activity across all three target receptors. These structural features collectively contribute to the favorable pharmacokinetic profile of Retatrutide, characterized by high bioavailability, sustained plasma concentrations, and predictable accumulation after repeated dosing. The physical properties of Retatrutide include good solubility in DMSO and alkaline solutions, with a pH of approximately 5.0 to 6.5 when reconstituted at 1 milligram per milliliter in water. The lyophilized powder is white to off-white in appearance and forms a clear, colorless solution upon proper reconstitution with sterile water for research use, 0.9% saline, or sterile bacteriostatic water. Stability studies have shown that the lyophilized powder remains stable for at least 24 months at -20°C, for at least 12 months at 4°C, and for at least seven days at 25°C when protected from light. After reconstitution, the solution should be stored at 4°C and used within 24 to 48 hours, or aliquoted and frozen at -20°C for up to one month, with repeated freeze-thaw cycles strictly avoided.
The mechanism of action of Retatrutide is fundamentally different from all other incretin-based peptides because it simultaneously activates three distinct hormone receptors: GIP, GLP-1, and glucagon. This triple receptor agonism produces complementary and synergistic effects on glucose metabolism, body weight regulation, and energy expenditure that cannot be achieved with single or dual agonists. When Retatrutide binds to GIP receptors on pancreatic beta cells, it activates intracellular cyclic adenosine monophosphate (cAMP) signaling pathways, leading to glucose-dependent insulin secretion. The term "glucose-dependent" means that insulin release is strongly stimulated only when blood glucose levels are elevated, and the effect is significantly reduced when blood glucose is normal, a characteristic that greatly lowers the risk of hypoglycemia. In addition to promoting insulin secretion, GIP receptor activation also supports beta cell survival and function by promoting beta cell proliferation and reducing apoptosis, which contributes to long-term pancreatic health. GIP also influences lipid metabolism in adipose tissue, promoting healthy fat distribution, and may positively influence bone formation through receptors present on osteoblasts. Meanwhile, activation of the GLP-1 receptor produces its own set of beneficial effects. GLP-1 potentiates insulin release from pancreatic beta cells in a glucose-dependent manner, inhibits glucagon secretion from pancreatic alpha cells to reduce hepatic glucose production, delays gastric emptying to reduce postprandial glucose spikes, and acts on GLP-1 receptors in the hypothalamus to increase satiety and reduce food intake. What makes Retatrutide truly unique is the addition of glucagon receptor agonism. Glucagon is a hormone that normally works in opposition to insulin, promoting glucose production and lipolysis. However, when combined with GIP and GLP-1 activation, glucagon receptor agonism produces several beneficial metabolic effects. Glucagon increases energy expenditure by promoting thermogenesis in brown adipose tissue, enhances lipolysis and fatty acid oxidation, reduces food intake through central mechanisms, and improves lipid profile by reducing triglycerides and increasing HDL cholesterol. The combination of GIP, GLP-1, and glucagon receptor activation produces effects that are greater than the sum of their individual contributions, resulting in superior glycemic control, more substantial and sustained body weight reduction, increased energy expenditure, favorable changes in lipid profile, and a reduction in gastrointestinal side effects compared to what might be expected from single or dual agonism alone.
Retatrutide is widely used in various areas of metabolic research, and its triple agonism mechanism opens up new possibilities that were previously unavailable to researchers. In type 2 diabetes research, Retatrutide serves as a valuable tool for studying the complementary roles of GIP, GLP-1, and glucagon in glucose homeostasis, investigating glucose-dependent insulin secretion mechanisms, exploring beta cell preservation and regeneration, evaluating combination therapies for diabetes management, and advancing personalized medicine approaches based on incretin and glucagon response profiles. In obesity and weight management research, the potent weight-reducing effects of Retatrutide, which are significantly greater than those observed with dual or single agonists, make it an excellent research tool for investigating central nervous system pathways that regulate appetite, studying energy expenditure and metabolic rate through glucagon-mediated thermogenesis, researching body composition changes during weight loss, and evaluating long-term weight maintenance strategies. In metabolic syndrome research, Retatrutide affects multiple components of metabolic syndrome, making it suitable for studies on dyslipidemia and lipid metabolism, hypertension and blood pressure regulation, insulin resistance and metabolic dysfunction, and inflammatory markers associated with metabolic disease. In cardiovascular research, preclinical studies suggest that GIP, GLP-1, and glucagon receptor activation may have direct and indirect cardiovascular benefits, including improved endothelial function, reduced atherosclerosis progression, favorable cardiac remodeling, and reduced inflammatory pathways. The addition of glucagon agonism may provide additional cardiovascular benefits through increased energy expenditure and improved lipid profile. In non-alcoholic fatty liver disease research, Retatrutide has shown significant promise in reducing hepatic steatosis, inflammation, and fibrosis through multiple mechanisms, including direct effects on hepatic lipid metabolism, increased fatty acid oxidation, and reduced de novo lipogenesis. This makes Retatrutide particularly valuable for studies on hepatic lipid metabolism, fibrosis progression and regression, the gut-liver axis in metabolic disease, and combination therapies for NAFLD and NASH. In energy metabolism research, Retatrutide provides a unique tool for studying the role of glucagon in energy homeostasis, investigating the mechanisms of adaptive thermogenesis, exploring the interplay between different metabolic hormones, and developing new therapeutic strategies for metabolic diseases.
United States
United Kingdom
Poland
Austria
Australia
Pls input... 
Pls input...